 | |
| Company type | Subsidiary |
|---|---|
| Nasdaq: AMLN | |
| Industry | Biotechnology |
| Founded | 1987 |
| Defunct | 2014 |
| Fate | Acquired by Bristol-Myers Squibb and AstraZeneca |
| Headquarters | San Diego, California, United States |
Key people | Daniel M. Bradbury[1] |
| Products | Symlin (pramlintide) Byetta (exenatide) Bydureon (exenatide long-acting release) |
| Revenue |  US$651 million (2011)[2] |
| US$−543 million (2011)[2] | |
| Total assets |  US$1.87 billion (2011)[2] |
| Total equity | US$−139 million (2011)[2] |
Number of employees | 1,300 (2011)[2] |
| Subsidiaries | Amylin Ohio LLC |
Amylin Pharmaceuticals, Inc. is a biopharmaceutical founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended release).
- ^ "Company Profile for Amylin Pharmaceuticals Inc (AMLN)". Retrieved 2008-10-21.
- ^ a b c d e "Form 10-K". www.sec.gov. Retrieved 2017-05-26.